Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Assets (2016 - 2025)

Iovance Biotherapeutics has reported Assets over the past 13 years, most recently at $913.2 million for Q4 2025.

  • Quarterly results put Assets at $913.2 million for Q4 2025, changed 0.3% from a year ago — trailing twelve months through Dec 2025 was $913.2 million (changed 0.3% YoY), and the annual figure for FY2025 was $913.2 million, changed 0.3%.
  • Assets for Q4 2025 was $913.2 million at Iovance Biotherapeutics, up from $904.9 million in the prior quarter.
  • Over the last five years, Assets for IOVA hit a ceiling of $966.7 million in Q1 2025 and a floor of $757.3 million in Q2 2023.
  • Median Assets over the past 3 years was $887.4 million (2024), compared with a mean of $868.7 million.
  • Biggest five-year swings in Assets: increased 16.67% in 2024 and later grew 0.3% in 2025.
  • Iovance Biotherapeutics' Assets stood at $780.4 million in 2023, then grew by 16.67% to $910.4 million in 2024, then rose by 0.3% to $913.2 million in 2025.
  • The last three reported values for Assets were $913.2 million (Q4 2025), $904.9 million (Q3 2025), and $907.4 million (Q2 2025) per Business Quant data.